On the other hand, B1R is inducible and is expressed in major inflammatory pathologies such as cardiovascular diseases and cancer [17], [18], making it an attractive pharmaceutical target with anticipated reduced collateral effects. The gene discussed is BDKRB1; the disease is cancer.